Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study

Traders Union
All News
Companies
Nurix launches CLL drug trial

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Market Voices

Companies

Artem Shendetskii

17.07.2026

Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study — Nurix launches CLL drug trial

Nurix Therapeutics has launched its DAYBREAK-CLL-201 clinical trial to evaluate bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

The study focuses on the scientific rationale and design aimed at addressing treatment challenges in difficult-to-treat CLL cases. The company’s effort reflects ongoing innovation in hematology and underlines the importance of advancing new therapeutic options for patients.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Nurix Therapeutics has previously built momentum with its investigational oral BTK degrader bexobrutideg in trials for relapsed or refractory CLL, according to a recent update. The company also announced a strategic partnership with Roche to accelerate the bexobrutideg program. Both developments support Nurix’s ongoing efforts in CLL drug development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Pokémon cards for $2,500: How collectibles became a new form of gambling

By Pavlo Kot
18 hours ago

Pokémon cards for $2,500: How collectibles became a new form of gambling

Editors' Picks

The privacy paradox: How the crypto mixer market has changed

By Pavlo Kot
Yesterday

The privacy paradox: How the crypto mixer market has changed

Editors' Picks

Is Bitcoin right for you? Five traits shared by many cryptocurrency holders

By Oleg Tkachenko
17.07.2026

Is Bitcoin right for you? Five traits shared by many cryptocurrency holders

Editors' Picks

All Editors' Top Picks

Latest Nurix News

Nurix Therapeutics surges with new oral BTK degrader bexobrutideg momentum in CLL treatment

By Ashutosh Sureka
14.07.2026

Nurix Therapeutics surges with new oral BTK degrader bexobrutideg momentum in CLL treatment

Companies

Nurix Therapeutics forges strategic partnership with Roche to accelerate bexobrutideg program

By Igor Krasulya
10.07.2026

Nurix Therapeutics forges strategic partnership with Roche to accelerate bexobrutideg program

Companies

Nurix Therapeutics enters partnership with Roche to advance targeted protein degradation therapies

By Andreas Kristo
08.06.2026

Nurix Therapeutics enters partnership with Roche to advance targeted protein degradation therapies

Companies

Pavlo Kot
18 hours ago

Pokémon cards for $2,500: How collectibles became a new form of gambling

Pavlo Kot
Yesterday

The privacy paradox: How the crypto mixer market has changed

Oleg Tkachenko
17.07.2026

Is Bitcoin right for you? Five traits shared by many cryptocurrency holders

Eugene Komchuk
17.07.2026

Chasing hits: Why investors are losing interest in Netflix

Mikhail Vnuchkov
16.07.2026

Tokenized stocks in the spotlight: How do they work and are they worth trading?

Yaroslav Dmytrenko
1 hour ago

Bitcoin market at familiar turning point, Jason Pizzino notes

Hanna Syniavska
1 hour ago

Brian Armstrong: Bitcoin hash power does not influence its price

Ivan Andriyenko
1 hour ago

Mark Roussin: Oil prices, big tech earnings, treasury yields to drive market this week

Jose Antonio Gastelum
1 hour ago

Layah Heilpern: Celebrating Solana with Jason in new video post

Andrey Mastykin
1 hour ago

Binary views on sugar market chart can coexist, Peter Brandt notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Pavlo Kot
18 hours ago

Pokémon cards for $2,500: How collectibles became a new form of gambling

Pokémon cards for $2,500: How collectibles became a new form of gambling

Pavlo Kot
Yesterday

The privacy paradox: How the crypto mixer market has changed

The privacy paradox: How the crypto mixer market has changed

Hanna Syniavska
17.07.2026

U.S. futures fall as Nvidia and chip stocks weaken

U.S. futures fall as Nvidia and chip stocks weaken

Andrey Mastykin
17.07.2026

UBS and Deutsche Bank back Europe's stock rally

UBS and Deutsche Bank back Europe's stock rally

Olga Shendetskaya
17.07.2026

Oil rises as Gulf tensions deepen

Oil rises as Gulf tensions deepen

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Microsoft rebounds from key support as AI momentum improves sentiment

Anton Kharitonov
Now

Apple breaks into record territory as AI optimism lifts shares to new highs

Mykhailo Ihnatenko
Now

AMD tests key support as AI profit-taking accelerates

Anton Kharitonov
Now

Bitcoin retreats below $63,500 as Middle East tensions trigger fresh risk-off selling

Anton Kharitonov
Now

WTI holds above $80 as Middle East tensions keep geopolitical premium elevated

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.